• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

Ramucirumab plus erlotinib receives FDA approval to treat metastatic NSCLC

September 7, 2020
-
News
-
Posted by admin
Ramucirumab-plus-erlotinib-receives-FDA-approval-admaconcology (1)

On 29 May 2020, the combination of erlotinib and ramucirumab received Food and Drug Administration (FDA) acceptance for managing metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 21 (L858R) substitution or exon 19 deletion mutations.

A randomized, multicentre, double-blind, placebo-controlled, multinational analysis (RELAY) was performed to investigate the efficacy of ramucirumab plus erlotinib combination in individuals with previously untreated metastatic EGFR-mutated NSCLC.

Overall, 449 participants were allocated to either receive 10 mg/kg ramucirumab arm or placebo arm every two weeks as an intravenous infusion group, in combination with erlotinib 150 mg orally once daily, until unacceptable toxicity or disorder advancement.

Progression-free survival (PFS) as evaluated by the investigator Response evaluation criteria in solid tumors (RECIST v1.1) was the major endpoint of the study. Overall survival(OS), duration of response, and overall response rate (ORR) were the additional efficacy endpoints.

The median PFS, ORR, and the median duration of response for both groups are depicted in the following table:

Ramucirumab plus erlotinib group Placebo plus erlotinib group
Median PFS 19.4 months 12.4 months
>ORR 76.00% 75.00%
Median duration of response 18 months 11.1 months

Notably, OS information was not found to be mature at the time of the final PFS assessment because of the occurrence of only 26% of the mortality required for the final evaluation.

Peripheral edema, hypertension, infections, stomatitis, alopecia, proteinuria, and epistaxis were the most usual adverse reactions witnessed. Hypokalaemia, anemia, thrombocytopenia, neutropenia, and elevated alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase were the most usual laboratory abnormalities.

The incidence rate of adverse events and laboratory abnormalities was higher in individuals treated with ramucirumab with erlotinib when compared to individuals treated with placebo with erlotinib as shown in the following table:

Ramucirumab plus erlotinib group Placebo plus erlotinib group
Occurrence of noxious reactions and laboratory abnormalities (%) 20% 2%

For treating individuals with metastatic NSCLC, the effective dosage of ramucirumab in combination with erlotinib is found to be 10 mg/kg every two weeks. Thus, a combination of ramucirumab with erlotinib is an effective first-line treatment approach to cure metastatic NSCLC.

You might also interested in knowing more FDA-approved chemo-therapeutics for different cancer cell lines; Nivolumabspan for esophageal squamous cell carcinoma, Lubrinectedin for metastatic SCLC orPHESGO for HER-2 positive bladder cancer.

Source US FDA
Link: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc [Last accessed on: 24 July, 2020]
Original title of the article FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
← PREVIOUS POST
FDA granted approval to Pembrolizumab for Colorectal Cancer Treatment
NEXT POST →
Berries: Potent Anti-Cancer Fruit

Related News

Other posts that you should not miss.
Guava-anticancer-fruit-admac

Guava: A potent anticancer fruit

January 19, 2021
-
News

Guava (Psidium guajava) is one of the most loved tropical fruits by the people of India. This fruit grows in wild places or in commercial groves all over …

Read More →
Posted by seoaccount medivisual
5 MIN READ
honey-for-cancer-patient-admac

Benefits of Honey for Cancer Patients

July 4, 2020
-
News

Depicted by Stone Age painting, the use of honey by humans is traced back to around 8000 years ago. Honey is a renowned natural palatable sweetener that extensively …

Read More →
Posted by seoaccount medivisual
3 MIN READ
health care in hand

Efficacy and safety of anastrozole for the treatment of estrogen-positive breast cancer

May 11, 2020
-
News

Breast cancer is one of the most common cancer and considered among the major reasons of cancer-associated mortality and morbidity in women. It is estimated that the global …

Read More →
Posted by admin
3 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
FDA Approves Ramucirumab Plus Erlotinib to Treat Metastatic NSCLC | Admac